3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

The Canadian market is experiencing strong momentum as it heads into 2025, supported by a resilient consumer base, rising corporate profits, and the beginning of a rate-cutting cycle. Amidst this positive backdrop, investors may find opportunities in areas that have traditionally been overlooked, such as penny stocks. While the term "penny stock" might seem outdated, these smaller or newer companies can still offer significant growth potential when backed by solid financials and fundamentals.

Top 10 Penny Stocks In Canada

Name	Share Price	Market Cap	Financial Health Rating
Alvopetro Energy (TSXV:ALV)	CA$4.33	CA$154.9M	★★★★★★
Amerigo Resources (TSX:ARG)	CA$1.71	CA$283.52M	★★★★★☆
Pulse Seismic (TSX:PSD)	CA$2.39	CA$120.08M	★★★★★★
PetroTal (TSX:TAL)	CA$0.63	CA$574.88M	★★★★★★
Mandalay Resources (TSX:MND)	CA$3.45	CA$324.12M	★★★★★★
Vox Royalty (TSX:VOXR)	CA$3.73	CA$187.19M	★★★★★★
Findev (TSXV:FDI)	CA$0.465	CA$13.03M	★★★★★☆
Foraco International (TSX:FAR)	CA$2.11	CA$212.76M	★★★★★☆
NamSys (TSXV:CTZ)	CA$1.14	CA$30.89M	★★★★★★
East West Petroleum (TSXV:EW)	CA$0.04	CA$3.62M	★★★★★★

Click here to see the full list of 959 stocks from our TSX Penny Stocks screener.

We'll examine a selection from our screener results.

InnoCan Pharma (CNSX:INNO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: InnoCan Pharma Corporation is a pharmaceutical technology company that develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients across the United States, Canada, Europe, and internationally, with a market cap of CA$65.99 million.

Operations: The company's revenue is primarily generated from online sales, amounting to $28.86 million.

Market Cap: CA$66M

InnoCan Pharma has demonstrated significant revenue growth, with third-quarter sales reaching US$8.62 million, doubling from the previous year. Despite being unprofitable, the company has reduced its net loss over recent periods and maintains a robust cash position with short-term assets of US$9.5 million covering both short- and long-term liabilities comfortably. The management team is experienced, aiding in strategic decisions like the FDA's positive response to their LPT-CBD product pathway, potentially expediting market entry. However, shareholder dilution occurred last year with a 7.1% increase in shares outstanding, which investors should consider when evaluating potential risks and rewards.

• Unlock comprehensive insights into our analysis of InnoCan Pharma stock in this financial health report.
• Understand InnoCan Pharma's track record by examining our performance history report.

Taranis Resources (TSXV:TRO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taranis Resources Inc. is an exploration stage company focused on acquiring, exploring, and developing precious and base metal deposits in Canada, with a market cap of CA$22.91 million.

Operations: Taranis Resources Inc. does not report any revenue segments as it is an exploration stage company focused on the development of metal deposits in Canada.

Market Cap: CA$22.91M

Taranis Resources Inc., with a market cap of CA$22.91 million, remains pre-revenue as it focuses on exploring and developing metal deposits. Recent updates on its Thor project in British Columbia revealed that the 2024 deep drilling program encountered challenges, including lost drill holes and a lack of significant mineralization in key areas. Despite these setbacks, the company continues to explore potential conductive features related to graphite presence. Financially, Taranis has reduced its net loss over recent quarters but faces liquidity constraints with short-term liabilities exceeding assets; however, recent capital raises may provide temporary relief.

• Jump into the full analysis health report here for a deeper understanding of Taranis Resources.
• Learn about Taranis Resources' historical performance here.

Zoomd Technologies (TSXV:ZOMD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zoomd Technologies Ltd. operates as a global marketing technology platform focused on user acquisition and engagement, with a market cap of CA$52.29 million.

Operations: The company generates revenue of $37.37 million from its Internet Software & Services segment.

Market Cap: CA$52.29M

Zoomd Technologies Ltd., with a market cap of CA$52.29 million, has shown significant financial improvement, becoming profitable last year and reporting a net income of US$2.69 million for the first half of 2024 compared to a previous loss. The company’s earnings quality is high, supported by strong cash flow coverage for its debt and interest obligations. Despite increased volatility in share price over the past year, Zoomd's valuation appears attractive with a price-to-earnings ratio below the industry average. Recent presentations at investor conferences suggest active engagement with investors and potential strategic developments on the horizon.

• Get an in-depth perspective on Zoomd Technologies' performance by reading our balance sheet health report here.
• Gain insights into Zoomd Technologies' historical outcomes by reviewing our past performance report.

Turning Ideas Into Actions

• Take a closer look at our TSX Penny Stocks list of 959 companies by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com